Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway

Anti-Cancer Drugs

Volumn 22, Issue 7, 2011, Pages 665-673

  Lau, Patrick Chi Pan ^a   Chan, Anthony Tak Cheung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

head and neck; hepatocyte growth factor; MET; squamous cell carcinoma

Indexed keywords

AMUVATINIB; BEVACIZUMAB; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FORETINIB; GELATINASE B; INTERLEUKIN 8; JNJ 38877605; MGCD 265; MITOGEN ACTIVATED PROTEIN KINASE; MK 2461; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SCATTER FACTOR RECEPTOR; MOTESANIB; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; TEMOZOLOMIDE; TIVANTINIB; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; XL 184;

ANGIOGENESIS; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL VIABILITY; CHEMOSENSITIVITY; COLORECTAL CARCINOMA; DIMERIZATION; DISEASE ASSOCIATION; DRUG BINDING; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EPSTEIN BARR VIRUS; EXTRACELLULAR MATRIX; GENE AMPLIFICATION; HEAD AND NECK CANCER; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; NASOPHARYNX CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HEPATOCYTE GROWTH FACTOR; HUMANS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79960454791     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328341879d     Document Type: Review

References (131)

1. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. editors. SEER cancer statistics review 1975-SEER cancer statistics review 2004. Bethesda, MD: National Cancer Institute; 2006.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59:225-249.
4. Argiris A, Eng C. Epidemiology, staging, and screening of head and neck cancer. Cancer Treat Res 2003; 114:15-60.
5. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-1956. (Pubitemid 46740304)
6. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298:70-82. (Pubitemid 47026772)
7. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53:3579-3584. (Pubitemid 23229640)
8. Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-1127.
9. Birchmeier C, Birchmeier W, Gheradi E, Van Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915-925. (Pubitemid 37493640)
10. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croco CM, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311:29-33. (Pubitemid 14065275)
11. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 1991; 251:802-804. (Pubitemid 21926175)
12. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. Tyrosines 1234-1235 are critical for activation of the tyrosine kinase encoded by the MET protooncogene (HGF receptor). Oncogene 1994; 9:49-57.
13. Ponzetto C, Bardelli A, Maina F, Longati P, Panayotou G, Dhand R, et al. A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Mol Cell Biol 1993; 13:4600-4608. (Pubitemid 23220367)
14. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77:261-271. (Pubitemid 24138623)
15. Furge KA, Zhang YW, Vande Woude G. Met receptor tyrosine kinase: enhanced signaling through adaptor proteins. Oncogene 2000; 19:5582-5589.
16. Michalopoulos G, Houck KA, Dolan ML, Leutteke NC. Control of hepatocyte replication by two serum factors. Cancer Res 1984; 44:4414-4419. (Pubitemid 14008758)
17. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984; 122:1450-1459. (Pubitemid 14073577)
18. Gohda E, Tsubouchi H, Nakayama H, Hirono S, Sakiyama O, Takahashi K, et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 1988; 81:414-419. (Pubitemid 18075233)
19. Rubin JS, Chan AM, Bottaro DP, Burgess WH, Taylor WG, Cech AC, et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci USA 1991; 88:415-419. (Pubitemid 21915475)
20. Sonnenberg E, Weider KM, Birchmeier C. Expression of the MET-receptor and its ligand, HGF-SF during mouse embryogenesis. EXS 1993; 65:381-394.
21. Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Vande Woude GF. The met proto-oncogene receptor and lumen formation. Science 1992; 257:1258-1261.
22. Santos O, Barros E, Yang XM, Matsumoto K, Nakamura T, Park M, et al. Involvement of hepatocyte growth factor in kidney development. Dev Biol 1994; 163:525-529. (Pubitemid 24221635)
23. Woolf AS, Kolatsi-Joannou M, Hardman P, Andermarcher E, Moorby C, Fine LG, et al. Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. J Cell Biol 1995; 128:171-184.
24. Soriano JV, Pepper MS, Nakamura T, Orci L, Montesano R. Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells. J Cell Sci 1995; 108:413-430.
25. Yang Y, Spitzer E, Meyer D, Sachs M, Niemann C, Hartmann G, et al. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol 1995;131:215-226.
26. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995; 376:768-771.
27. Streit A, Stern CD, Thery C, Ireland GW, Aparicio S, Sharpe MJ, et al. A role for HGF/SF in neural induction and its expression in Hensen's node during gastrulation. Development 1995; 121:813-824.
28. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995; 373:699-702.
29. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor, which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119:629-641.
30. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993; 90:1937-1941. (Pubitemid 23069972)
31. Nusrat A, Parkos CA, Bacarra AE, Godowski PJ, Delp-Archer C, Rosen EM, et al. Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia. J Clin Invest 1994; 93:2056-2065.
32. Jeffers M, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996; 74:505-513. (Pubitemid 26306792)
33. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994; 91:4731-4735. (Pubitemid 24177723)
34. Bellusci S, Moens G, Gaudino G, Comoglio P, Nakamura T, Thiery JP, et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 1994; 9:1091-1099. (Pubitemid 24095017)
35. Liang TJ, Reid AE, Xavier R, Cardiff RD, Wang TC. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 1996; 97:2872-2877. (Pubitemid 26197101)
36. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997; 94:701-706.
37. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001; 153:1023-1034.
38. Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, et al. RNA interference reveals that ligand-independent Met activity is required for tumor cell signaling and survival. Cancer Res 2004; 64:7962-7970. (Pubitemid 39446930)
39. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in nonsmall cell lung cancer. Cancer Res 2005; 65:1479-1488. (Pubitemid 40270177)
40. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring METgene amplification are dependent on Met for growth and survival. Cancer Res 2007; 67:2081-2088. (Pubitemid 46424226)
41. Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen DP, Chaganti RS. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990; 50:6417-6422. (Pubitemid 20323708)
42. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in-situ hybridization. Lab Invest 1998; 78:1143-1153. (Pubitemid 28440830)
43. Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006; 25:409-418. (Pubitemid 43117626)
44. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104:20932-20937.
45. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1:147-154.
46. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germ line and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73. (Pubitemid 27198158)
47. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19:4947-4953.
48. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997; 57:P5391-P5398.
49. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996; 148:225-232. (Pubitemid 26022451)
50. Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995; 10:739-749.
51. Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, et al. Suppression of ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci USA 2001; 98:10722-10727. (Pubitemid 32878688)
52. Ivan M, Bond JA, Prat M, Comoglio PM, Wynford-Thomas D. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997; 14:2417-2423. (Pubitemid 27268160)
53. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF. Met expression and sarcoma tumorigenicity. Cancer Res 1993; 53:5355-5360. (Pubitemid 23342148)
54. Rong S, Donehower LA, Hansen MF, Strong L, Tainsky M, Jeffers M, et al. Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 1995; 55:1963-1970.
55. Giordano S, Zhen Z, Medico E, Gaudino G, Galimi F, Comoglio PM. Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. Proc Natl Acad Sci USA 1993; 90:649-653. (Pubitemid 23028921)
56. Kenworthy P, Dowrick P, Baillie-Johnson H, McCann B, Tsubouchi H, Arakaki N, et al. The presence of scatter factor in patients with metastatic spread to the pleura. Br J Cancer 1992; 66:243-247.
57. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 1996; 16:1115-1125. (Pubitemid 26061683)
58. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol 1995; 131:1573-1586.
59. Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991; 67:901-908. (Pubitemid 121001504)
60. Niemann C, Brinkmann V, Spitzer E, Hartmann G, Sachs M, Naundorf H, et al. Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol 1998; 143:533-545. (Pubitemid 28487869)
61. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008; 18:87-96. (Pubitemid 351694452)
62. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004; 6:61-73. (Pubitemid 38903162)
63. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6:637-645. (Pubitemid 44140861)
64. Marshall DD, Kornberg LJ. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 1998; 108:1413-1417. (Pubitemid 28411378)
65. Chen YS, Wang JT, Chang YF, Liu BY, Wang YP, Sun A, et al. Expression of hepatocyte growth factor and c-met is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 2004; 33:209-217. (Pubitemid 38478507)
66. Kim CH, Moon SK, Bae JH, Lee JH, Han JH, Kim K, et al. Expression of hepatocyte growth factory and c-met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2006; 126:88-94. (Pubitemid 41769745)
67. Sawatsubashi M, Sasatomi E, Mizokami H, Tokunaga O, Shin T. Expression of c-met in laryngeal carcinoma. Virchows Arch 1998; 432:331-335. (Pubitemid 28171995)
68. Lo Muzio L, Farina A, Rubini C, Coccia E, Capogreco M, Colella G, et al. Effect of c-met expression on survival in head and neck squamous cell carcinoma. Tumour Biol 2006; 27:115-121.
69. Aebersold DM, Kollar A, Beer KT, Laissue J, Greiner RH, Djonov V. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 2001; 96: 41-54. (Pubitemid 32147684)
70. Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, Kort E, et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res 2004; 10:8204-8213. (Pubitemid 40053379)
71. Murai M, Shen X, Huang L, Carpenter WM, Lin CS, Silverman S, et al. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion. Int J Oncol 2004; 25:831-840.
72. Yucel OT, Sungur A, Kaya S. C-met overexpression in supraglottic laryngeal squamous cell carcinoma and its relation to lymph node metastases. Otolaryngol Head Neck Surg 2004; 130:698-703. (Pubitemid 38881222)
73. Galeazzi E, Olivero M, Gervasio FC, De Stefani A, Valente G, Comoglio PM, et al. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 1997; 254 (Suppl 1):S138-S143. (Pubitemid 27110381)
74. Cortesina G, Martone T, Galeazzi E, Olivero M, De Stefani A, Bussi M, et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 2000; 89:286-292. (Pubitemid 30430746)
75. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, De Stefani A, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000; 19:1547-1555. (Pubitemid 30175676)
76. Morello S, Olivero M, Aimetti M, Bernardi M, Berrone S, Di Renzo MF, et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J Cell Physiol 2001; 189:285-290. (Pubitemid 33063296)
77. Kitajo H, Shibata T, Nagayasu H, Kawano T, Hamada J, Yamashita T, et al. Rho regulates the hepatocyte growth factor/scatter factor-stimulated cell motility of human oral squamous cell carcinoma cells. Oncol Rep 2003; 10:1351-1356.
78. Matsumoto K, Matsumoto K, Nakamura T, Kramer RH. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 1994; 269:31807-31813.
79. Uchida D, Kawamata H, Omotehara F, Nakashiro K, Kimura-Yanagawa T, Hino S, et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vivo and its clinical significance. Int J Cancer 2001; 93:489-496. (Pubitemid 32701407)
80. Kim CH, Kim J, Kahng H, Choi EC. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma. Ann Surg Oncol 2007; 14:1565-1574. (Pubitemid 46791004)
81. Frixen UH, Behrens J, Sachs Eberle G, Voss B, Warda A, Lochner D, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113:173-185. (Pubitemid 21909684)
82. Grotegut S, Von Schweinitz D, Christofori G, Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK-Egr-1-mediated upregulation of snail. EMBO J 2006; 25:3534-3545. (Pubitemid 44264864)
83. Yokohama K, Kamata N, Hayashi E, Hoteiya T, Ueda N, Fujimoto R, et al. Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol 2001; 37:65-71.
84. Smith DE, Franco del Amo F, Gridley T. Isolation of Sna, a mouse gene homologous to Drosophila genes snail and escargot: its expression pattern suggests multiple roles during postimplantation development. Development 1992; 116:1033-1039. (Pubitemid 23042443)
85. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, Del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83.
86. Yokohama K, Kamata N, Fujomoto R, Tsutsumi S, Tomonari M, Taki M, et al. Increased invasion and matrix metalloproteinase-2 expression by snail-induced mesenchymal transition in squamous cell carcinomas. Int J Oncol 2003; 22:891-898.
87. Zeng Q, Chen S, You Z, Yang F, Carey TE, Saims D, et al. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkB. J Biol Chem 2002; 277:25203-25208. (Pubitemid 34951827)
88. Lim YC, Park HY, Hwang HS, Kang SU, Pyun JH, Lee MH, et al. (-)-epigallocatechin-3-gallate (ECGC) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett 2008; 271:140-152.
89. Hanzawa M, Shindoh M, Higashino F, Yasuda M, Inoue N, Hida K, et al. Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis 2000; 21:1079-1085. (Pubitemid 30389331)
90. Hida K, Shindoh M, Yasuda M, Hanzawa M, Funaoka K, Kohgo T, et al. Antisense E1AF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities. Am J Pathol 1997; 150:2125-2132. (Pubitemid 27233083)
91. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and P13K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 2001; 61:5911-5918. (Pubitemid 32769111)
92. Dong G, Lee TL, Yeh NT, Geoghegan J, Van Waes C, Chen Z. Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor. Oncogene 2004; 23:6199-6208. (Pubitemid 39215290)
93. Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 2005; 103:22-31. (Pubitemid 39665453)
94. Tao Q, Chan ATC. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007; 9:1-24. (Pubitemid 47398642)
95. Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002; 62:589-596. (Pubitemid 34106436)
96. Horikawa T, Sheen T, Takeshita H, Sato H, Furukawa M, Yoshizaki T. Induction of c-Met proto-oncogene by epstein-barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 2001; 159:27-33. (Pubitemid 33704188)
97. Kim KR, Yoshizaki T, Miyamori H, Hasegawa K, Horikawa T, Furukawa M, et al. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene 2000; 19:1764-1771. (Pubitemid 30200982)
98. Matsumoto K, Nakamura T. NK4(HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003; 94:321-327. (Pubitemid 36626362)
99. Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG102, in cynomolgus monkeys. Pharm Res 2007; 24:1910-1918. (Pubitemid 47389247)
100. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-met-dependent human tumors. Cancer Res 2006; 66:1721-1729. (Pubitemid 43259957)
101. Reardon DA, Cloughsey TF, Raizer JJ, Laterra J, Schiff D, Yang X, et al. Phase II study of AMG102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme (Abstr 2051). J Clin Oncol 2008; 26 [Abstract].
102. Gordon MS, Mendelson DS, Sweeney C, Erbeck N, Patel R, Kakkar T, et al. Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors (Abstr 3551). J Clin Oncol 2007; 25 [Abstract].
103. Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A, et al. AMG102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87MG cells and xenografts. Clin Cancer Res 2007; 13:6735-6742. (Pubitemid 350206811)
104. Rosen PJ, Sweeney CJ, Park DJ, Beaupre DM, Deng H, Leitch IM, et al. A phase Ib study of AMG102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010; 16:2677-2687.
105. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144-6152. (Pubitemid 44703780)
106. Salgia R, Peterson A, Eppler S. A phase I, open label, dose escalation study of the safety and pharmacology of MetMAb, A monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors. Presented at the 20th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2008 Oct 21-24; Geneva (Switzerland): Abstr 411.
107. Mekhail T, Rich T, Rosen L, Chai F, Semic-Suka Z, Savage RE, et al. Final results: a dose escalation phase I study of ARQ197, a selective c-Met inhibitor, in patients with metastatic solid tumors (Abstr 3548). J Clin Oncol 2009; 27 [Abstract].
108. Perera T, Lavrijssen T, Janssens B. JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models. Presented at the 99th AACR Annual Meeting; 2008 April 12-16; San Diego (CA): Abstr 4837.
109. Zou H, Li Q, Joseph L. PF-04217903, a novel selective c-Met kinase inhibitor with potent antitumor and anti-angiogenic properties in vitro and in vivo. Presented at the 99th AACR Annual Meeting; 2008 Apr 12-16; San Diego (CA): Abstr 4841.
110. Christiansen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6:3314-3322.
111. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67:4408-4417. (Pubitemid 46815090)
112. Kwak EL, Camidge DR, Clark J, Shapiro GI, Maki RG, Ratain MJ, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 (Abstr 3509). J Clin Oncol 2009; 27 [Abstract].
113. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009; 69:8009-8016.
114. Eder JP, Heath E, Appleman L, Shapiro G, Wang D, Malburg L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors (Abstr 3526). J Clin Oncol 2007; 25 [Abstract].
115. LoRusso P, Appleman L, Zhu A. Pharmacodynamics of XL880, a novel spectrum selective kinase inhibitor (SSKI) administered orally in patients with advanced solid tumors (AST) (Abstr 404). Eur J Cancer Suppl 2006; 4 [Abstract].
116. Eder JP, Appleman L, Heath E. A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs) (Abstr 3041). J Clin Oncol 2006; 24 [Abstract].
117. Jänne PA, Wax M, Leach J, Engelman JA. Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical design (Abstr 552). Eur J Cancer 2008; 6 [Abstract].
118. Salgia R, Hong DS, Camacho LH, Ng S, Janisch L, Ratain MJ, et al. A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies (Abstr 14031). J Clin Oncol 2007; 25 [Abstract].
119. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) (Abstr 3522). J Clin Oncol 2008; 26 [Abstract].
120. Tolcher A, Berk G, Fine G. MP470, a potent oral Rad51 suppressor is safe and tolerable in first-in-human study. Presented at the 99th AACR Annual Meeting; 2008 Apr 12-16; San Diego (CA): Abstr 4083.
121. Beaulieu N, Beaulieu C, Dupont I. Preclinical development of MGCD265, a potent orally active c-Met/VEGFR multi-target kinase inhibitor. Presented at the 99th AACR Annual Meeting; 2008 Apr 12-16; San Diego (CA): Abstr 4838.
122. Camacho LH, Moulder SL, LoRusso PM, Blumenschein GR, Bristow PJ, Kurzrock R, et al. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors (Abstr 14657). J Clin Oncol 2008;26 [Abstract].
123. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009; 15:3740-3750.
124. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, Dinali ME, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009; 69:3021-3031.
125. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043. (Pubitemid 46799492)
126. Mueller KL, Hunter LA, Ethier SP, Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008; 68:3314-3322.
127. Merchant M, Zhang Y-W, Su Y. Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors. Presented at 99th AACR Annual Meeting; 2008 April 12-16; San Diego (CA): Abstr 1336.
128. Merchant M, Zhang Y, Su Y. MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models. Presented at the 20th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2008 October 21-24; Geneva (Switzerland): Abstr 556.
129. Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, et al. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Mol Cancer Res 2010; 8:1142-1151.
130. Laux I, Goldman J, Just R, Brady K, Li J, Schwartz B, et al. Phase I dose escalation trial (ARQ197-111) evaluating combination of selective c-Met inhibitor ARQ197 and erlotinib (Abstr 3549). J Clin Oncol 2009; 27 [Abstract].
131. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103:2316-2321. (Pubitemid 43271667)